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Notwithstanding different meningococcal serogroups have 
changed their distribution and their impact in different age 
classes over time, N. meningitidis’ invasive diseases are a 
major public health issue worldwide, due to the related com-
plications and severe sequelae. Nowadays, the highest rates of 
invasive disease are registered in children younger than 1 year 
of age, with a second lesser peak in adolescents and young 
adults (15-25 years of age). On the contrary, the prevalence 
of carriage is low in newborns and in school-age children, 
and increases during adolescence and young-adult age; then it 
decreases again in older age. N. meningitidis’ infection prev-
alence has greatly decreased in Europe and North America 
thanks to the use of conjugate vaccines (MenC and MenACWY) 
as well as the incidence of invasive disease due to serogroup 
A in sub-saharian Africa after the introduction of MenAfriVac 
conjugate vaccine.
The great success of conjugate vaccines is related not only to the 
direct protection from disease but also to the impact on carriage; 
this latter allows an indirect protection of unimmunized subjects. 
For these reasons, the implementation of immunization with the 
new generation vaccines in the age classes most impacted by dis-
ease and carriage (first year of life, adolescence and young adult-
hood) could permit to achieve an extraordinary decrease of the 
incidence of meningococcal disease. 
Review
Epidemiology of Neisseria meningitidis infections:  
case distribution by age and relevance of carriage
G. Gabutti, a. Stefanati, P. Kuhdari 
department of Medical Sciences, university of ferrara, italy
Key words
Neisseria meningitidis • Age classes • Carriage
Summary
Introduction
Neisseria meningitidis (N. meningitidis) is an aerobic, 
Gram-negative diplococcus, exclusively hosted by man; 
it usually lives as a temporal commensal in the upper 
respiratory tract without causing any disease. Reasons 
for the transition from asymptomatic carriage to inva-
sive disease have still not completely understood; any-
way, some factors, such as genetic and capsular struc-
ture of pathogenic strains, are believed to play a relevant 
role [1, 2]. N. meningitidis is classified in 12 serogroups 
(accordingly to capsular polysaccharide structure) and 
in serotypes and sub-serotypes (accordingly to outer 
membrane proteins). The role played by each most epi-
demiological relevant serogroup (A, B, C, W-135, and 
Y) greatly changes in relation to time period and geo-
graphical area considered; anyway, notwithstanding the 
ample underestimate of its global epidemiological im-
pact, meningococcus is a relevant public health issue 
worldwide [3, 4].
N. meningitidis is transmitted through respiratory drop-
lets of infected subjects or, more often, of asymptomatic 
carriers. Usually humoral immune response is enough to 
prevent the spreading of the pathogen and the occur-
rence of invasive disease. Anyway, if the humoral re-
sponse is not adequate, bacteriaemia occurs due to not 
yet completely understood mechanisms [5]. Once in the 
bloodstream, meningococci circumvent immunologi-
cal response by several virulence factors (capsule, IgA 
protease, surface “blebs” containing LPS, that act as an 
endotoxin). Endotoxin induces a cascade of pro-inflam-
matory citokines with a subsequent endotelial damage, 
increase of vascular permeability, protrombotic condi-
tion with subsequent development of microthrombosis. 
Meningococcal disease is a quite rare event and menin-
gitis is its most common feature (about 50% of cases) 
[6], followed by bacteriaemia (40% of cases). Fulminant 
disease occurs in 10-20% of cases and it is characterized 
by organ failure and disseminated intravascular clot-
ting (e.g. Waterhouse-Friderichsen syndrome); in these 
cases, mortality could be equal to 50% [7]. Lethality of 
meningococcal infections could reach 10%, while per-
manent sequaelae occur in up to 20% of survivors. Per-
manent sequelae involve neurological damage, psycho-
logical disturbances, hearing loss, visual loss, cutaneous 
scarring and/or limb amputations [8].
Pathogenesis and Epidemiology
The global incidence of meningococcal disease greatly 
changes in relation to considered geographical areas; 
worldwide, 500,000-1,200,000 invasive meningococcal 
diseases occur each year, with 50,000-135,000 deaths 
[9,10].
Nowadays, in Europe, North America and Australia 
incidence ranges between 0.3 and 3 cases per 100,000 
inhabitants [11], while the same could reach 10-1,000 
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cases/100,000 in Africa during epidemics (in particular 
in the so-called sub-saharian “meningitis belt”).
The epidemiology of meningococcal infections has sig-
nificantly changed over the years in many regions of the 
world. Serogroup A has been the principal agent of inva-
sive meningococcal disease in Europe before and during 
I and II World Wars, serogroup B has been prevalent 
since 1970 in Europe and since 1980 in South America; 
epidemic outbreaks due to W-135 and Y serogroups 
have emerged more recently during the XXIst century. 
Besides, a change in the age classes affected by invasive 
disease has occurred, with an increase of incidence of 
serogroup Y in elderly and a decrease of serogroup C in 
adolescents. The epidemiological trend of invasive dis-
ease has almost remained unchanged in Africa, where 
serogroup A is most prevalent; very recently, serogroups 
X and W-135 have had a relevant impact in terms of 
morbidity and mortality [12].
Disease caused by serogroup A in Africa has an annual 
incidence equal to 10-20 cases per 100,000 inhabitants; 
epidemic outbreaks, occurring during dry season, im-
ply an attack rate greater than 1,000 cases per 100,000. 
Data from Latin America and Asia are limited. In Latin 
America, incidence ranges between 0.1/100,000 in Mex-
ico to 2 cases/100,000 in Brasil, with a predominance 
of serogroups B and C [13]. In Asia, the epidemiologi-
cal burden of meningococcal disease is not well de-
fined. Serogroup A has been considered prevalent; any-
way, all five serogroups (A, B, C, Y and W-135) have 
been reported, even if with a regional variation [14]. In 
Australia, meningococcal incidence is greater than 3 
case/100,000. In most American and European countries 
a low level of endemicity is registered. In 2011 [15], 29 
European countries (27 UE countries plus Norway and 
Iceland) have reported 3,808 confirmed cases of inva-
sive disease; the global notification rate has been equal 
to 0.77/100,000 (range 0.09-1.99), serogroup B has been 
the most relevant (73.6% of cases), followed by sero-
group C (14.4%) and Y (8.2%). Invasive disease inci-
dence sustained by serogroup B in Europe accounted for 
0.5 cases per 100,000 inhabitants. Italy reports the low-
est incidence rate, equal to 0.25 case per 100,000 [16]. 
Figure 1 shows the distribution of main N. meningitidis 
serogroups in different geographical areas.
Age classes and categories at risk  
of developing meningococcal disease
There is an ample consensus that the categories at highest 
risk of developing meningococcal disease are newborns 
and children in the first year of life (as natural immunity 
against N. meningitids is particularly low), adolescents 
(due to their habits and behaviours that facilitate strict 
interpersonal contacts; besides, they have the highest 
carriage rate), travellers that stay for long time in endem-
ic areas (Sub-saharian Africa, ect.), immunosuppressed 
subjects (functional or anatomic asplenia, thalassemia, 
sickle cell anemia, persistent complement deficiencies, 
organ transplant, cancer or high dosage corticosteroid 
therapy, diabetes, HIV infection, congenital immunode-
ficiencies), and elder subjects [17, 11].
The highest rate of disease is registered in children 
younger than 1 year of age, with a second lower peak in 
adolescents and young adults (15-25 years of age) [18].
Since 2008, European incidence rate has decreased form 
0.95/100,000 to 0.68/100,000; higher rates have been 
registered in Lituania and UK (1.77 and 1.36, respec-
tively). Newborns, 1-4year-old children and adolescents 
(15-25 years of age) are the most affected subjects in all 
Fig. 1. meningococcal serogroups in the world (reference 9, modified).
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countries, irrespective of ongoing or not immunization 
programs against MenC.
The most relevant rate of invasive disease, in particu-
lar in children younger than 5 years of age, is related 
to serogroup B, followed by serogroup C. In 2012, the 
notification rate of MenB infection in children <1 year 
of age has been three-fold higher than the one registered 
in the age group 1-4 years (12.3 and 4.1 per 100,000, 
respectively). The highest rate of MenC cases has been 
registered among young adults and adults (25-44 years 
of age); serogroup Y has been mostly identified in >65 
year-old subjects [19].
In Italy, Azzari e co-workers have confirmed, in a study 
conducted in the period 2006-2012 [20], that as in other 
European countries, meningococcal disease caused by 
serogroup B has a greater incidence during the first 5 
years of life and that 70% of cases are registered dur-
ing the first year of age, with a peak between 4 and 8 
months.
As far as immunization with MenC conjugated vaccine 
has been implemented in Italian regions, the incidence 
of the disease related to this serogroup has progressively 
decreased. Nowadays, serogroup B is the most common 
serogroup causing invasive meningococcal disease, be-
ing involved in more than 80% of cases in patients <24 
years of age. Figure 2 shows the distribution of MenB 
invasive disease in Italy in the period 2007-2012, and its 
peak of incidence in the first year of life [16].
In USA, the rate of invasive meningococcal disease has 
been equal to 0.14/100,000 in 2013; incidence mainly in-
volved children younger than 5 years and subjects aged 
18-35 years (in the two groups the incidence was almost 
equal: 1.7/100,000). Serogroup B impacted mostly in 
<1year-old babies (0.68/100,000), while serogroup C 
showed an higher incidence in the age class 1-4 years 
(0.41/100,000) [21].
Carriage
N. meningitidis is a human infective agent usually resid-
ing in the nasopharynx. Human upper respiratory tract 
is a stable ecological niche; anyway, meningococci can 
be habitual components of the microbial flora in buc-
cal mucosa, anus, urethra, urogenital mucosa, and dental 
plaque. Carriage at pharingeal level involves 8-25% of 
subjects; this means hundreds of millions people in the 
world, adolescents being the most relevant group [22].
The relationship between asymptomatic carriage and de-
velopment of invasive disease in not completely known, 
nor the timeframe necessary for the transition from one 
status to the other. Concerning this point, humoral im-
munity certainly plays a crucial role. In most cases the 
microorganism persists in the nasopharynx for days or 
weeks, and even months. Carriage is crucial not only in 
the transmission dynamics but even in the onset of inva-
sive disease. As a matter of fact, the lack of bactericidal 
antibodies is a relevant risk factor for the transition to 
invasive disease. The repeated occurrence of carrier sta-
tus, not only of N. meningitidis but also of N. lactamica, 
even not protective against subsequent new carriage, can 
elicit a cross-protection against invasive disease [23].
Strains in carriers are genetically and antigenically dif-
ferent from the ones isolated in subjects affected by in-
vasive disease. Age is one of the most relevant factor 
related to meningococcal carriage.
Carrier status has been studied and even more in depth 
understood during last years, in particular after the imple-
mentation of immunization with MenC conjugate vaccine 
Fig. 2. estimated incidence of invasive menB disease in Italy, 2007-2012 (data from reference 16).
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and the achievement of relevant results in terms of epide-
miological and immunological impact. Differently from 
natural infection, carriage has a low prevalence in the first 
years of life and in older age classes, and reaches its peak 
in adolescents and young adults. In the “meningitis belt” 
meningococci are, in respect to other geographical areas, 
more uniformly distributed irrespective from age [24].
Besides, more than age, other factors influence carriage 
such as male gender, concomitant viral or bacterial res-
piratory infections, active and passive smoke, low socio-
economic status. One of the most relevant risk factor is 
the number and the mixing pattern of social interactions; 
seasonality does not seem relevant [25].
Both in Europe and in North America, the highest rate of 
nasopharingeal carriage is registered in adolescents and 
in young adults; they act as the most relevant source of 
infection. Carriage prevalence increases from 4.5% in 
infancy to a peak of 23.7% in the age class 19-20 years, 
and then decreases to about 10% in adults [26, 27]. 
These data have been recently confirmed in a study per-
formed in Italy evaluating the molecular and serological 
diversity of N. meningitidis carrier strains isolated from 
students aged 14 to 22 years [28].
Vaccines and herd immunity
Knowledge on the epidemiology of N. meningitidis, the 
role of carriers and the invasive disease, has allowed to 
better understand both the relevance and the impact of 
immunization. There is an ample consensus on the point 
that immunization is the best and most efficacious pre-
ventive approach against meningococcal disease.
Since ’70-’80s polysaccharide vaccines against serogroups 
A, C, Y and W-135 have been available. Later, conjugate 
vaccines has been developed; these vaccines, differently 
from polysaccharide ones, elicit a T-dependent immune 
response with the production of high affinity antibodies, 
immune memory and responsivity to subsequent doses. 
Conjugate vaccines are efficacious also in newborns, have 
an impact on carriage and induce herd immunity.
For all these reasons, the availability of conjugate vac-
cines and the implementation of immunization programs 
has allowed to achieve a great impact on the epidemiol-
ogy of meningococcal disease. Since 2005, the evaluation 
of the results obtained after the immunization program 
adopted in UK has demonstrated that MenC conjugate 
vaccine directly protects immunized subjects, decreases 
carriage and blocks the spreading of the agent [24]. All 
these effects have amplified the impact of vaccination 
against serogroup C even in age classes not directly in-
volved in the immunization program [29]. Another study 
performed in Africa in 2012 has showed a persistent de-
crease of carriage following the use of a MenA conjugate 
vaccine (MenAfriVac); carriage prevalence decreased 
from 0.39% in the pre-immunization period to 0,02% two 
years after the implementation of vaccination [30].
In addition to conjugate vaccines against serogroups A, C, 
Y and W-135, since January 2013 a new 4-components 
MenB vaccine (4cMenB) has been licensed in Europe. 
Read and co-workers in UK have recently evaluated the 
impact on carriage after immunization with Men ACWY-
CRM conjugate (1 dose) and 4CMenB (2 doses; time 
interval between doses: 1 month) vaccines in university 
students aged 18-24 years [31]. The impact on carriage of 
both vaccines has been evaluated 1 month and during the 
12 months following immunization. Concerning 4cMenB, 
since the 3rd month after administration a significant de-
crease of carriage of any meningococcal strain (18.2%), 
capsular groups BCWY (26.6%), capsular groups and se-
rogroups CWY (29.6% and 28.5%, respectively) has been 
registered. A significant decrease of carriage rate has been 
registered also in subjects immunized with MenACWY-
CRM compared to controls; the decrease was equal to 
39% and 36.2% for serogroup Y and CWY, respectively. 
This study confirms that 4cMenB vaccine could impact 
on carriage not only for meningococcus B but also for 
other serogroups, as it does not contain capsular antigens 
but proteins shared with other nonB serogroups. Anyway, 
even if this study shows a first evidence of the impact on 
carriage of 4cMenB vaccine (as well as of MenACWY-
CRM vaccine), its results should be considered with cau-
tion; the impact on carriage at individual level cannot be 
considered predictive of herd immunity. As a matter of 
fact, several other factors play a relevant role in the de-
terminism of herd immunity, not only the ability of the 
vaccine to block or decrease the acquisition of the car-
riage status.
 Conclusions
Notwithstanding the results achieved in the fight against 
disease caused by N. meningitidis, this etiological agent 
continues to be a relevant worldwide treat for health. 
Knowledge about age classes at highest risk and about 
relationship between nasopharingeal carriage and dis-
ease is fundamental in order to understand epidemiol-
ogy and pathogenesis of meningococcal disease and to 
identify adequate immunization strategies.
Newborns and children <1year of age are at highest risk 
for the disease as their immune system is not completely 
developed and the maternal passive immunity tends to 
progressively fade out. The highest prevalence rate of 
carriage is registered in adolescents and young adults; 
in these age groups the efficacy of conjugate vaccines 
against carriage is equal to 75% [32].
The incidence of meningococcal disease has decreased 
during the last decade thanks to the immunization pro-
grams with conjugate vaccines against serogroups A, C, 
Y, W-135. More recently the new 4CMenB vaccine has 
been introduced with the aim to decrease the incidence 
of the disease sustained by serogroup B.
All these vaccines are safe, well tolerated and highly ef-
ficacious against the most relevant invasive serogroups; 
they elicit a long-lasting immune response in all age 
groups and induce herd immunity.
For all these reasons, the implementation of immuniza-
tion programs against meningococcal disease should be 
a public health priority.
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